Celcuity, Inc., a cellular analysis company based in Minneapolis, went public in 2017 and employs 45 people. Its main product, gedatolisib, targets specific cancer pathways and is in trials for treating advanced breast cancer.
Celcuity (CELC) reported a positive EPS surprise in its most recent quarterly earnings. For the most recent quarter, Celcuity's actual EPS was -$0.62, beating the estimate of -$0.69 per share, resulting in a 10.42% surprise.
📡️ Health Care
Earnings Surprise
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
